BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Palo Alto Networks (NasdaqGS:PANW) from Buy to Neutral. Analyst Price Forecast Suggests 22.11% Upside As of December 23, 2024, ...

On Wednesday, Nuvation Bio Inc (NUVB) stock saw a decline, ending the day at $3.01 which represents a decrease of $-0.24 or -7.38% from the prior close of $3.25. The stock opened at $3.32 and touched ...

Anavex Life Sciences Corp’s profitability metrics reveal financial health. The company currently boasts a gross margin of 147.40%. The profit margin, also known as the revenue ratio or gross profit ...

“In 2025, the energy sector will be less about barrels of oil and more about...billions of cubic feet of natural gas demand ...

Fulton Bank N.A. reduced its stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 1.3% in the 4th quarter, ...

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) has earned an average recommendation of “Hold” from the seven ...

After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued success for pulsed field ablation as trends to watch this year.

KeyBanc analyst Justin Patterson maintained a Buy rating on DoorDash (DASH – Research Report) today and set a price target of $225.00. The ...